

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LaBella Nicholas A. Jr.</u> (Last) (First) (Middle) C/O ZYVERSA THERAPEUTICS, INC. 2200 N. COMMERCE PARKWAY, SUITE 208 (Street) WESTON FL 26333 (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>ZyVersa Therapeutics, Inc. [ ZVSA ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Scientific Officer		
			3. Date of Earliest Transaction (Month/Day/Year) 12/12/2022					
			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/12/2022		A		18,094	A	(I)	18,094	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Options (right to buy)	\$5.03	12/12/2022		A		19,854		(2)	04/11/2024	Common Stock	19,854	\$0	19,854	D	
Stock Options (right to buy)	\$5.03	12/12/2022		A		39,709		(3)	06/09/2025	Common Stock	39,709	\$0	39,709	D	
Stock Options (right to buy)	\$5.03	12/12/2022		A		59,563		(4)	10/30/2027	Common Stock	59,563	\$0	59,563	D	
Stock Options (right to buy)	\$11.58	12/12/2022		A		39,708		(5)	04/02/2029	Common Stock	39,708	\$0	39,708	D	
Stock Options (right to buy)	\$16.36	12/12/2022		A		29,781		(6)	02/08/2031	Common Stock	29,781	\$0	29,781	D	
Stock Options (right to buy)	\$16.36	12/12/2022		A		29,781		(7)	01/28/2032	Common Stock	29,781	\$0	29,781	D	
Warrant (right to buy)	\$6.9	12/12/2022		A		18,094		(8)	12/12/2027	Common Stock	18,094	\$0	18,094	D	

**Explanation of Responses:**

- Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old ZyVersa as the surviving company of the Acquisition Merger and, after giving effect to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.
- 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015.
- 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on June 9, 2016.
- 100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017.
- 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.
- The option vests in 3 equal annual installments commencing on February 8, 2022.
- The option vests in 3 equal annual installments commencing on January 28, 2023.
- The warrant is immediately exercisable in full.

/s/ Peter Wolfe, attorney-in-fact for Nicholas A. LaBella 12/14/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**